Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03764-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Elaheh Hassani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran. Hauptthemen laut MEDLINE: Metformin, Doxorubicin, CD8-Positive T-Lymphocytes, Mammary Neoplasms, Experimental. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Breast cancer is a leading cause of cancer-related deaths among women worldwide. The presence and function of CD8 + T cells in the tumor microenvironment have been associated with better patient outcomes. Drug toxicity has posed a significant challenge to the clinical implementation of chemotherapy-based strategies in cancer treatment. METHODS: In this study, we employed flow cytometry to investigate the potential synergistic immunomodulatory effects on CD8 + T cells in a mouse model of breast cancer by combining metformin, an anti-diabetic medication, with doxorubicin. RESULTS: Through flow cytometry analysis, we observed that the combination of the two drugs led to an increased percentage of CD8 + T cells compared to either drug alone. The modulation of HIF-1α and STAT3 gene expression in the combination group further confirmed the efficacy of this approach. CONCLUSIONS: Our findings suggest that combining metformin with doxorubicin can enhance the anticancer activity of doxorubicin and decrease its cytotoxicity in a 4T1 breast cancer mouse model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
- Department of Immunology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
- Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran. a.mohimm@gmail.com.
- Department of Immunology and Genetics, Urmia University of Medical Sciences, Urmia, Iran. a.mohimm@gmail.com.
Zitieren
APA
Hassani, E., Mozzendizaji, S., Shafiei-Irannejad, V., & Mohammadzadeh, A. (2024). Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03764-2
Vancouver
Hassani E, Mozzendizaji S, Shafiei-Irannejad V, Mohammadzadeh A. Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03764-2
BibTeX
@article{Hassani2024,
author = {Hassani, Elaheh and Mozzendizaji, Sahand and Shafiei-Irannejad, Vahid and Mohammadzadeh, Adel},
title = {Metformin boosts doxorubicin efficacy and increases CD8 + T cell frequency in mouse breast cancer},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03764-2}
}
EUVIMED